Nucleic-Acid Sequence Amplification by Primer Extension
Full Analysis

Invention Disclosure Review

Nucleic-Acid Sequence Amplification by Primer Extension

Generated
Jul 20, 2026

Generated on a public invention disclosure — no confidential material involved. First-pass analysis — not an opinion of counsel or drafted claims.

1.

Cross-Domain Application Map

Clinical infectious-disease diagnostics — Detecting bacterial, viral, or other pathogen signatures present at trace levels in a patient specimen by amplifying a pathogen-specific bounded region to a readily detectable amount.

The generalized function's defining strengths — geometric accumulation from vanishingly small starting material plus a product delimited to the region chosen by the two flanking initiators — deliver both extreme sensitivity and target specificity, and the fully in-vitro cycle avoids the delay and hazard of culturing the organism. This is the origin-field, file-first use where the closest and most dangerous prior art lives.

Evidence: described_not_demonstrated · Application distance: near

Molecular measurement / quantitation — Determining how much of a target sequence is present in a sample — e.g., pathogen load, gene copy number, or transcript abundance — by relating the cycle count needed to reach a set amount back to the starting quantity.

The disclosed geometric per-cycle doubling (accumulation approximated by a defined exponential relationship) makes the number of cycles to reach a threshold a direct read-out of initial template amount, converting the amplification engine into a quantitative measurement tool rather than a mere presence/absence test.

Evidence: speculative · Application distance: adjacent

Inherited-disease and prenatal genetic testing — Amplifying a specific gene region from a limited clinical sample (few cells, biopsy, or fetal-derived material) so a mutation or variant can be analyzed without culturing cells.

Programmable selection of the bounded region by the two flanking initiators isolates the diagnostically relevant locus, and geometric amplification from scarce starting material removes the need for cell propagation to obtain analyzable quantities.

Evidence: described_not_demonstrated · Application distance: near

Research / biotechnology enabling workflows — Rapidly generating usable quantities of a defined sequence for cloning inserts, sequencing template preparation, synthetic gene assembly, and primer-directed sequence editing.

The in-vitro cycle replaces slow host-organism propagation for producing material, while the initiators both define exactly which segment is produced and can carry engineered changes into the product, making the function a general-purpose sequence-manufacturing and editing tool across molecular biology.

Evidence: described_not_demonstrated · Application distance: near

Forensic and identity DNA analysis — Amplifying identity-informative loci from trace, mixed, or partially degraded biological material recovered from crime scenes, disaster remains, or kinship/paternity samples.

Recovery of a readable amount from vanishingly small or damaged starting material is the exact hard need in forensics, and the short bounded product defined by the flanking initiators tolerates fragmented templates while targeting the specific typing region. This sits in a different professional field (law enforcement/legal) from clinical diagnostics.

Evidence: speculative · Application distance: adjacent

Oncology / liquid biopsy — Detecting rare tumor-derived molecules (e.g., mutant sequences) among a large background of normal cell-free fragments circulating in blood or other body fluids.

Extreme trace sensitivity combined with a product delimited to a chosen mutation-bearing region allows a very small number of tumor-origin molecules to be selectively amplified above background, enabling minimally invasive detection and monitoring — a non-obvious deployment of the same amplify-from-trace function.

Evidence: speculative · Application distance: adjacent

2.

Claim Architecture

The claim-level view (the primary analysis): the broadest defensible claim is on the mechanism itself — it covers every use — while a standalone same-mechanism application claim is weak. This is engineering work-product / a scaffold for counsel, NOT drafted claims or a patentability conclusion. Grounded in the prior art available to this report; confirm against a full search before relying on it.

Broadest mechanism (the dominating claim): A cyclic in-vitro process for geometrically replicating a defined segment of a nucleic-acid template using two oligonucleotide primers, each complementary to a different strand of the target and flanking the segment to be copied, present in large molar excess, wherein each cycle (i) hybridizes both primers to their respective template strands, (ii) enzymatically extends each primer along its template to form a duplex, and (iii) separates the duplexes so that the extension product of each primer serves as template for the other primer in the next cycle — such that repeated cycling drives approximately 2^n accumulation of the region bounded by the two primer binding sites. The mechanism is the repeated hybridize/extend/separate cycle acting on a bounded, primer-delimited segment; the disclosure supports strand separation by thermal denaturation and does not depend on any particular polymerase species.

Process claim set

Covers: two oligonucleotide primers each complementary to a different strand of the double-stranded target, primer extension product of one primer serves as template for extension of the other primer, repeated treat/extend/separate cycle (thermal cycling), heat denaturation at ~80–105 °C to separate extension products from templates, primer hybridization at or near ambient temperature; extension at ~25–40 °C, exponential accumulation (~2^n − n − 1 double strands after n cycles) of the primer-bounded region, entirely in-vitro enzymatic amplification without host propagation/cloning

Closest prior art: Paper: 'Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system' (1992) — two primers (P1, P2) present in excess, each binding a target strand, driving amplification; also related is 'Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication' (1990). Background references D1 (single-primer linear extension) and D3 (host-cloning) are farther.

Distinguishing limitation: Strand separation and re-templating accomplished by REPEATED THERMAL DENATURATION of the extension-product duplexes (products becoming templates each cycle), rather than isothermal enzymatic strand separation requiring an auxiliary restriction/nicking or transcription step. The closest isothermal art achieves exponential growth only via restriction-recognition/nicking or a multienzyme transcription loop; it does not disclose the cyclic heat-denature / anneal / extend regime driving geometric doubling of the two-primer-bounded segment. (Note: the retrieved 'Primer-Directed Enzymatic Amplification with a Thermostable DNA Polymerase' paper appears to describe the same cyclic mechanism with a thermostable enzyme; counsel must verify its date/relationship, as it may be same-inventor/improvement art rather than distinguishable prior art.)

Standard: §102/§103 (for counsel to assess)

System claim set

Covers: two oligonucleotide primers (each ~15–25 nt) flanking a bounded target region, each complementary to a different strand, molar excess of primers relative to template (~1000:1 for cloned DNA, up to ~1e6:1 for genomic DNA), bounded-region architecture — product defined and delimited by the two primer binding sites, extension enzyme operating in a hybridize/extend/separate reaction environment

Closest prior art: Patent US20220033891A1 (forward and reverse primers with target serving as template, amplified segment as predominant product) and Patent US11466315B2 (reaction mixture with at least two primers annealing to complementary strands of a double-stranded nucleic acid). (verify)

Distinguishing limitation: The reaction composition defined by the paired-primer molar excess (on the order of ~1000:1 up to ~1e6:1 primer:template) configured so that each primer's extension product becomes the other primer's template, delimiting a bounded segment by the two primer binding sites. The cited patents recite forward/reverse primers but do not disclose this specified large primer molar-excess regime paired with the reciprocal product-as-template bounded architecture as claimed. (Rest the distinction on the compositional excess and reciprocal-template relationship, not on any total-yield metric.)

Standard: §103 obviousness (for counsel to assess)

Method-of-use claim set

Covers: use of the bounded-region exponential amplification for detection, diagnostics, and downstream analysis

Closest prior art: Patents CN114250278B and CN116121349B (use of paired-primer amplification/qPCR for detection and quantification) and US11466315B2 (STR genotyping application). (verify)

Distinguishing limitation: Applying the amplification mechanism to detection/diagnostic endpoints is presumptively a predictable use (KSR) and is described_not_demonstrated in the disclosure; a standalone use claim is weak absent a showing that a specific application required non-obvious adaptation. Any defensible distinction here would have to reside in a specific, non-routine adaptation of the amplification chemistry to the assay — not identified as such in the present disclosure. Flag for counsel: pursue only if a concrete non-obvious application-specific limitation exists.

Standard: §103 obviousness / KSR predictable-use (for counsel to assess)

3.

Novelty & Nonobviousness Stress Test

Inventive-Step Stress Test

The adversarial pass: the strongest case AGAINST the moat, so counsel sees the threats before an examiner or opponent does. Challenges rest only on the prior art available to this report; inventor-asserted premises are checked against that art rather than repeated as fact. Engineering work-product — it names §102/§103, it does not conclude.

The greatest threat to the moat is the repair-replication line of work in the provided art — above all the Kleppe/Khorana 'Studies on polynucleotides XCVI' paper (and its companion XC paper), which predates any plausible priority and is historically understood to have described primer-directed enzymatic copying of a defined duplex with a primer on each strand and to have contemplated repeating the copy after strand separation. If its full text recites the repeated cycle and denaturation-based strand separation, it goes directly to the core cyclic mechanism under both §102 and §103, and it also undercuts the inventor's framing that prior amplification 'required' cloning or de-novo synthesis. A secondary threat is that the two-primer exponential/bounded-segment architecture — asserted as the distinguishing concept — is independently reached by the isothermal 1990/1992 papers, so that concept alone is a thin place to rest novelty. The headline 10^6-fold-in-20-cycles number is arithmetically trivial and should not be leaned on. The strongest surviving position for counsel to develop is narrow and mechanism-specific: the distinction lies not in 'two primers,' 'exponential,' 'bounded region,' or 'in vitro' (each of which is echoed somewhere in the provided art), but in achieving geometric doubling of a primer-delimited segment specifically by REPEATED THERMAL DENATURATION of the extension-product duplexes so that each product becomes a template each cycle — a regime the isothermal art deliberately avoids (it uses nicking/restriction or a transcription loop) and one whose reduction to practice is corroborated by the measured ~70% per-cycle efficiency and product specificity rather than by total fold-amplification. Counsel should verify (a) the exact teaching and date of Kleppe XCVI, and (b) whether the thermostable-polymerase Science paper is same-inventor/improvement art, before finalizing how much weight the thermal-cycling distinction can bear.

Strongest challenges to the distinguishing limitations

  • Strand separation and re-templating by REPEATED THERMAL DENATURATION driving geometric (~2^n) doubling of a two-primer-bounded segment. — substantial — counsel must weigh

    • The Kleppe/Khorana repair-replication work ('Studies on polynucleotides XCVI. Repair replication of short synthetic DNA's as catalyzed by DNA polymerases,' with related 'Studies on polynucleotides XC. DNA polymerase-catalyzed repair of short DNA duplexes with single-stranded ends') is the single most threatening piece here. This line of work described enzymatic primer-directed copying of a defined duplex segment using primers complementary to each strand, and the XCVI paper is historically understood to have contemplated repeating the copy after strand separation with two primers to replicate a bounded region — i.e., the conceptual hybridize/extend/separate loop. If the full text recites repeating the cycle and separating strands by denaturation, it bears directly on both §102 and §103 for the core cyclic mechanism — counsel must weigh it. Its date (circa 1971) predates any plausible priority, unlike most other retrieved references.
    • Rests on: Studies on polynucleotides XCVI. Repair replication of short synthetic DNA's (and companion XC paper) (provenance: verify_full_doc)

  • Same cyclic thermal-denature/anneal/extend regime, as an alternative anchor. — weak challenge

    • 'Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase' (Science) appears to describe the identical cyclic mechanism with a thermostable enzyme. On its face this bears squarely on §102/§103 for the process — but the disclosure itself flags it as likely same-inventor/improvement (Cetus/Taq) art rather than independent prior art. Counsel must verify its date and inventorship relationship before treating it as adverse; if it is same-inventor later work it is not §102 prior art, though it may still be relevant to obviousness-type or priority questions.
    • Rests on: Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase (provenance: verify_full_doc)

  • Two-primer exponential amplification where each primer's extension product becomes the other's template (reciprocal product-as-template bounded architecture) with primers in large molar excess. — substantial — counsel must weigh

    • The 1990 multienzyme retroviral-model paper and the 1992 restriction-enzyme/DNA-polymerase paper both disclose two primers (P1, P2) present in excess, each binding a different target strand and driving exponential amplification of a bounded region — the reciprocal-template, two-primer-in-excess architecture. They bear on the compositional/architectural limitation for §103. TWO caveats counsel must weigh: (i) both papers post-date a foundational PCR priority, so they are adverse only if the effective date is later than assumed; and (ii) they achieve strand separation isothermally via nicking/restriction or a transcription loop, not by repeated thermal denaturation — so they reach the two-primer exponential architecture without the thermal-cycling limitation. The reciprocal architecture concept is thus not itself unique, but the thermal-cycling means of achieving it may survive.
    • Rests on: Isothermal in vitro amplification (1992); Isothermal multienzyme retroviral-model amplification (1990) (provenance: grounded)

  • The specific large primer molar-excess regime (~1000:1 to ~1e6:1 primer:template). — no challenge found in the provided art

    • No provided reference recites this specific numeric excess ratio paired with the bounded reciprocal-template architecture. Repair-replication and the isothermal papers use excess primers generally, and LATE-PCR (2005) addresses primer concentration ratios (but for deliberately UNEQUAL primer concentrations, a different purpose and post-dating). Nothing in the provided art bears on the specific ~1000:1/~1e6:1 regime as a distinguishing feature.

  • Application of the amplification mechanism to detection/diagnostic endpoints (method-of-use). — substantial — counsel must weigh

    • CN114250278B and CN116121349B (paired-primer amplification/qPCR for detection and quantification) and US11466315B2 (paired-primer amplification for STR genotyping) show that once the amplification chemistry exists, using it for detection/quantification is routine and predictable (KSR predictable-use). This bears on §103 for any standalone use claim. Caveat: all three post-date a foundational PCR priority, so they illustrate predictability rather than serving as anticipatory prior art; the disclosure itself concedes the use is described_not_demonstrated and identifies no non-routine assay-specific adaptation.
    • Rests on: CN114250278B; CN116121349B; US11466315B2 (verify) (provenance: grounded)

Inventor-asserted premises, checked against the art

  • Target sequences are often present in vanishingly small amounts, requiring amplification for detection. (industry_norm) — supported by the provided art

    • The detection/quantification patents (CN114250278B small-RNA detection, US11466315B2 STR genotyping) presuppose low-abundance targets and pre-amplification, consistent with the premise. Generic and non-controversial background.

  • Prior amplification approaches required laborious low-efficiency de-novo synthesis or propagation/cloning in a host organism. (industry_norm) — contradicted by the provided art

    • The provided repair-replication references (Kleppe/Khorana XCVI and XC; and the Kornberg enzymatic-synthesis papers on oligonucleotide templates and primer extension) show an in-vitro enzymatic primer-directed copying route existed that did not require cloning or de-novo synthesis. This undercuts the framing that cloning/de-novo synthesis were REQUIRED. Cloning and de-novo synthesis did exist and were laborious, but they were not the only in-vitro option — weakening the 'required' assertion.

  • The process achieves ~1,000,000-fold amplification after ~20 cycles. (performance_target) — supported by the provided art

    • Data-backed in the disclosure and internally consistent (2^20 ≈ 1e6). No external provided reference corroborates or refutes the specific figure, but it is an arithmetic consequence of the exponential mechanism rather than an independently surprising result.

  • Exponential yield accumulates as approximately (2^n − n − 1) double strands after n cycles. (performance_target) — uncorroborated (inventor-asserted; not shown by the provided art)

    • This is a theoretical derivation (doubling with a correction for the initial linear/long products); no provided reference addresses it. It is a model, not an independently verified performance figure — carries little independent inventive weight.

  • ~70% per-cycle efficiency demonstrated over 15 cycles. (performance_target) — uncorroborated (inventor-asserted; not shown by the provided art)

    • Data-backed in the disclosure; no provided reference speaks to it. This is the actual experimental performance figure and the one most worth defending — a search for prior per-cycle-efficiency reporting in enzymatic copying would test it.

  • The process avoids hazards and delay associated with propagation in a host organism. (comparative_advantage) — supported by the provided art

    • D3 (cloning-based amplification) is characterized as laborious with associated hazards and delay; an in-vitro process trivially avoids host propagation. True as a factual advantage, but this advantage is shared by any cell-free enzymatic route, including the repair-replication art — so it does not by itself distinguish the invention.

  • Exponential (chain-reaction) doubling and two-primer bounded-region architecture distinguish this process from linear single-primer extension. (comparative_advantage) — contradicted by the provided art

    • As a contrast to D1 (single-primer linear extension) the statement holds, but as an assertion that two-primer exponential/bounded amplification is itself the point of novelty it is undermined: the isothermal 1990/1992 papers already achieve two-primer exponential amplification of a bounded segment (albeit isothermally and likely post-dating), and the Kleppe repair-replication work contemplated two-primer repeated copying. The durable distinction is the THERMAL-CYCLING means of strand separation, not the two-primer exponential concept per se.

  • Entirely in-vitro enzymatic amplification eliminates the need for cloning in a host organism. (comparative_advantage) — supported by the provided art

    • Factually true of the process. But 'in-vitro without cloning' is not unique to this invention — the repair-replication and cell-free polymerase-extension references are also in-vitro. The advantage is real but not distinguishing on its own.

Performance-metric scrutiny

  • ~1,000,000-fold amplification after ~20 cycles — trivially satisfied by a conventional element — not where the novelty lives

    • Why: This is arithmetic: any process with near-doubling per cycle reaches ~10^6-fold at 20 cycles (2^20 ≈ 1.05e6). The headline fold-number is delivered automatically by the exponential mechanism itself and cannot carry the novelty — a large cycle count makes total fold easy the way a big battery makes total range easy.
    • Metric that actually distinguishes the invention: Per-cycle amplification efficiency (~70%) AND the specificity/purity of the bounded, primer-delimited product (fraction of product that is the intended segment vs. spurious extension) — the metrics that reflect whether the thermal-cycling chemistry actually works, not just how many cycles were run.

  • (2^n − n − 1) double strands after n cycles — trivially satisfied by a conventional element — not where the novelty lives

    • Why: A closed-form derivation of ideal doubling with a correction term for the initial long/linear products; it follows directly from the reciprocal product-as-template mechanism and describes expected behavior rather than a measured advantage.
    • Metric that actually distinguishes the invention: Measured deviation from ideal doubling — i.e., the demonstrated per-cycle efficiency and product specificity that show the mechanism performs near the theoretical model.

  • ~70% per-cycle efficiency over 15 cycles — carries weight

    • Metric that actually distinguishes the invention: This is itself the distinguishing metric — sustained near-doubling efficiency across many thermal denaturation/anneal/extend cycles, coupled with retention of product specificity.
4.

Claim Outline

Claim Scaffold

A drafting scaffold for counsel — plain-language claim CONCEPTS and fallback positions to turn into claims, NOT drafted claims and NOT legal advice. The broadest claim is on the mechanism (it covers every use); each dependent rung is a narrower fallback if the independent claim is narrowed. Every item is tagged by the disclosure support behind it (§112).

Independent claim — Process

Concept: A cyclic in-vitro method for geometrically increasing the number of copies of a defined segment of a nucleic-acid template, in which two oligonucleotide primers — each complementary to a different strand of the target and positioned so that they flank the segment to be copied — are provided in molar excess and repeatedly carried through three operations: hybridizing each primer to its template strand, enzymatically extending each primer along its template to form a duplex, and separating the duplexes by heating so that the extension product of one primer becomes the template for the other primer in the following round, whereby repeated cycling drives approximately exponential accumulation of the primer-bounded segment. Grounded only in the disclosed hybridize/extend/heat-separate regime and not tied to any particular polymerase species. (§112 support: data-backed)

Core elements: two oligonucleotide primers each complementary to a different strand of the double-stranded target, primers flanking the segment (bounded-region architecture), primer extension product of one primer serves as template for extension of the other primer, repeated treat/extend/separate cycle, strand separation by thermal denaturation, entirely in-vitro without host propagation/cloning

Dependent ladder (broad → narrow):

  • strand separation accomplished specifically by repeated heat denaturation of the extension-product duplexes each cycle (as opposed to isothermal enzymatic strand separation via nicking/restriction or a transcription loop) — distinguishes the cyclic thermal regime from isothermal exponential-amplification art that relies on restriction-recognition/nicking or a multienzyme transcription loop (§112 support: data-backed)
  • heat denaturation performed at approximately 85–100 °C — the narrower demonstrated denaturation window; commercially typical operating range (§112 support: data-backed)
  • denaturation held for approximately 1–10 minutes per cycle — captures the disclosed dwell time as a fallback if the broad temperature limitation is challenged (§112 support: data-backed)
  • primer hybridization carried out at or near ambient temperature and primer extension carried out at approximately 25–40 °C — the specific demonstrated thermal profile of the anneal and extend steps (§112 support: data-backed)
  • cycling repeated for approximately 13–20 rounds — the demonstrated cycle count producing exponential accumulation; a concrete process embodiment (§112 support: data-backed)
  • template is cloned double-stranded DNA amplified at a primer:template molar excess on the order of ~1000:1 — the fully worked, data-backed embodiment (15 cycles at ~70% per-cycle efficiency; ~1,000,000-fold after ~20 cycles) (§112 support: data-backed)
  • broad denaturation temperature range of approximately 80–105 °C — broader fallback around the demonstrated window for enzymes/templates requiring higher or lower melt (§112 support: described, no data)
  • template is genomic DNA amplified at a primer:template molar excess up to approximately 1e6:1 — extends the reciprocal-template mechanism to the more complex genomic starting material (§112 support: described, no data)

Independent claim — System

Concept: A reaction composition for bounded-segment nucleic-acid amplification, characterized by a pair of oligonucleotide primers each complementary to a different strand of the target and positioned to flank and delimit the segment to be copied, present in large molar excess relative to template, together with an extension enzyme operable in a hybridize/extend/separate environment, the composition being configured so that each primer's extension product serves as the template for the other primer, thereby defining the amplified product by the two primer binding sites. The distinction rests on the paired-primer molar-excess regime combined with the reciprocal product-as-template bounded architecture, not on any yield metric. (§112 support: data-backed)

Core elements: two oligonucleotide primers, each ~15–25 nt, each complementary to a different strand, primers flanking and delimiting a bounded target region, molar excess of primers relative to template (~1000:1 up to ~1e6:1), reciprocal product-as-template relationship, extension enzyme in a hybridize/extend/separate environment

Dependent ladder (broad → narrow):

  • primers are oligodeoxyribonucleotides of approximately 15–25 nucleotides in length — the disclosed primer chemistry and length; fallback if the primer genus is narrowed (§112 support: data-backed)
  • primer:template molar excess on the order of ~1000:1 for a cloned double-stranded DNA template — the data-backed compositional embodiment (§112 support: data-backed)
  • primer:template molar excess up to approximately 1e6:1 for a genomic DNA template — captures the higher-excess regime needed for complex templates as a commercial embodiment (§112 support: described, no data)
  • the two primer binding sites define and delimit the boundaries of the amplified product such that product length is set by the inter-primer distance — reinforces the bounded-region architecture against primers that merely initiate open-ended synthesis (§112 support: data-backed)

Independent claim — Method-of-use

Concept: Use of the bounded-region exponential amplification mechanism to generate detectable quantities of a specific primer-delimited sequence for detection, diagnostic, or downstream-analysis endpoints. Flagged as weak on its own: applying the amplification to a detection/diagnostic readout is described but not demonstrated and is presumptively a predictable use; a defensible use claim would need a concrete, non-routine adaptation of the amplification chemistry to the specific assay, which the present disclosure does not identify. (§112 support: described, no data)

Core elements: bounded-region exponential amplification of a specific target, detection / diagnostic / downstream-analysis endpoint

Dependent ladder (broad → narrow):

  • amplification of a target sequence to a copy level sufficient for direct detection without host cloning or propagation — ties the use to the in-vitro-only character of the mechanism; still requires counsel to assess predictable-use risk (§112 support: described, no data)

Blocking claims (for obvious design-arounds)

  • Workaround: Substituting a thermostable polymerase so denaturation and extension can be run at higher temperatures without re-adding enzyme each cycle Block with: A genus-level cyclic amplification concept in which strand separation is by repeated heat denaturation and extension is by any polymerase capable of operating across the cycled thermal profile, drafted so it is not limited to a mesophilic enzyme — provided counsel first resolves whether the 'thermostable DNA polymerase' paper is same-inventor/improvement art rather than distinguishable prior art before relying on this breadth. (§112 support: described, no data)

  • Workaround: Effecting strand separation by a non-thermal means (e.g., chemical denaturant, helicase, or pH shift) while keeping the two-primer reciprocal-template cycle Block with: A cycle-based amplification concept claiming separation of the extension-product duplexes by any denaturing step that regenerates single-stranded templates for the next round, with thermal denaturation as the lead species and other denaturing means as genus members — support to be assessed by counsel, as only thermal separation is disclosed. (§112 support: speculative)

  • Workaround: Using more than two primers, nested primers, or a primer plus a downstream blocking element to define the bounded segment Block with: A concept covering two or more primers cooperating so that each primer's extension product templates another primer's extension, delimiting the amplified region by primer binding sites — capturing multiplexed/nested variants of the reciprocal-template architecture. (§112 support: speculative)

  • Workaround: Adjusting the primer:template ratio to just below the claimed ~1000:1 floor to avoid the compositional limitation while still driving exponential accumulation Block with: A compositional concept resting on 'molar excess sufficient to sustain reciprocal product-as-template exponential accumulation' as the functional genus, with the ~1000:1–~1e6:1 range as the disclosed species, so a modestly lower ratio still reads on the functional recitation — for counsel to weigh against §112 definiteness. (§112 support: described, no data)

  • Workaround: Using RNA primers or mixed RNA/DNA primers instead of oligodeoxyribonucleotides Block with: A primer genus concept reciting oligonucleotide primers broadly (not limited to oligodeoxyribonucleotides) each complementary to a different strand and flanking the bounded segment, with the DNA primer as the demonstrated species. (§112 support: speculative)

Notes: Strongest §112 support sits with the cloned-DNA, ~1000:1 excess, ~85–100 °C denaturation, ambient anneal, 25–40 °C extension, 13–20 cycle embodiment — this is data_backed (15 cycles at ~70% per-cycle efficiency; ~1,000,000-fold at ~20 cycles) and should anchor the independent process and system claims and their lower ladder rungs. Rungs reciting genomic DNA at up to ~1e6:1 excess and the broad 80–105 °C range are described_not_demonstrated; counsel should consider whether a working genomic example is needed before relying on them as fallback positions. All blocking concepts reaching beyond thermal denaturation, beyond DNA primers, or below the disclosed excess range are speculative extensions offered for counsel's assessment, not conclusions of enablement or scope. CRITICAL PRIOR-ART FLAG for counsel: the retrieved 'Primer-Directed Enzymatic Amplification with a Thermostable DNA Polymerase' reference appears to describe the same cyclic mechanism — verify its date and inventive-entity/relationship (possible same-inventor or improvement art) before resting any distinction on the thermostable-enzyme genus or on breadth of the polymerase recitation. The method_of_use set is weak absent a concrete non-obvious application-specific adaptation; recommend pursuing it only if such a limitation can be identified and supported. No novelty, non-obviousness, or validity conclusions are drawn here — those determinations are reserved to counsel.

5.

Prior-Art Differentiation Notes

Per-Application Prior-Art Notes

Note

This is engineering work-product, not a legal opinion or a clearance/validity search. It names the legal standards; the patentability conclusions are the attorney’s.

How to read this section (the §103 framework, stated once): under Graham/KSR, obviousness turns on the scope and content of the prior art, the differences from the claims, the level of ordinary skill, and objective indicia — and any reason to combine references must be articulated, never hindsight. The per-application notes below POSITION each use against that framework; the deeper, claim-level inventive-step analysis is treated separately, at the level of the mechanism’s claims.

Each application is triaged as either "spec support only" (a predictable same-mechanism use — valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim) or "claim candidate" (required non-obvious adaptation — may merit a claim of its own).

Clinical infectious-disease diagnostics — Detecting bacterial, viral, or other pathogen signatures present at trace levels in a patient specimen by amplifying a pathogen-specific bounded region to a readily detectable amount.

Closest existing work: D3 — cloning-based amplification by propagation in a host organism, the pre-existing route to obtaining detectable amounts of a pathogen sequence for diagnostics; characterized in the disclosure as laborious, low-efficiency, and carrying culture-associated hazard and delay. (The retrieved patents — e.g., US11466315B2, US20220033891A1 — are downstream PCR refinements that presuppose the invention's core two-primer thermal-cycling mechanism rather than pre-dating it.)

Differentiation: Comparison is abstract-level (D3 is a background characterization, not claim text): the invention's named elements — two flanking primers in molar excess, each extension product serving as template for the other primer, repeated heat-denature/hybridize/extend cycles, and exponential (~2^n) accumulation of the primer-bounded region entirely in vitro — replace host-organism propagation entirely, so D3 discloses none of the in-vitro two-primer exponential-cycling elements. §102 novelty / §103 for counsel to assess.

Triage: spec support only — a predictable same-mechanism use; valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim

Citations:

  • D3 — Inventor-cited prior diagnostic route (culturing/cloning in a host) that the in-vitro exponential two-primer cycle displaces; closest for the pathogen-detection use. (provenance: grounded)
  • D1 — Single-primer linear extension — lacks the second flanking primer and the reciprocal-template exponential cycle that define this invention. (provenance: grounded)
  • US11466315B2 (verify) — Two-primer thermal-cycling amplification of a bounded region — same core mechanism but a later refinement (STR genotyping, fast cycling); illustrates that the diagnostic use is a same-mechanism application, not a re-engineering. (provenance: verify_full_doc)

Standard: §102 novelty (for counsel to assess)

Inventive-step consideration (§103 argument): For this diagnostic application, the §103 inquiry should distinguish the mechanism from its use: applying an already-defined two-primer exponential amplification to detect trace pathogen sequences is a predictable use of a known tool (extreme sensitivity from geometric accumulation + specificity from the bounded primer-defined region map directly onto the diagnostic need), so the diagnostic framing adds little independent non-obviousness. The genuine §103 weight lies in whether the named architecture itself — two flanking primers in molar excess where each extension product templates the other, cycled with ~85–100 °C denaturation — is obvious over the cited background D1 (single-primer linear extension) and D2 (repair-replication).

Articulated reason (KSR): A PHOSITA seeking a culture-free, rapid pathogen assay had a clear motivation to amplify a trace target, and once reciprocal-primer exponential cycling exists, pointing it at a pathogen-specific bounded region is a straightforward predictable application; the harder articulated-reason question is whether anything in D1/D2 supplies a reason to add a second flanking primer and iterate so each product becomes a template — the cited background teaches only single-primer linear or repair-type extension, not the reciprocal-templating exponential loop, so a combination reaching the claimed architecture risks resting on hindsight.

Reasonable expectation of success: For the diagnostic use, success is predictable once the amplification method works. But whether a PHOSITA extending D1's single-primer linear extension would have reasonably expected the reciprocal two-primer scheme to yield the claimed ~(2^n − n − 1) geometric accumulation is less certain — the specific denaturation window (~85–100 °C, 1–10 min), near-ambient hybridization, 25–40 °C extension, and the demonstrated ~70% per-cycle efficiency over 15–20 cycles are empirical parameters not evidently predictable from the linear-extension background alone.

Secondary considerations (each needs a nexus):

  • Long-felt need — nexus: Strong nexus if shown: rapid, sensitive detection of trace pathogen sequences without culturing ties directly to the exponential-accumulation and entirely-in-vitro named elements — but the characterization of culture (D3) and de-novo synthesis (D4) as 'laborious, low-efficiency, hazardous' is the inventor's own disclosure characterization; corroboration from an independent reference documenting that need would strengthen it, and it currently rests partly on an asserted norm.
  • Unexpected results — nexus: Nexus to the reciprocal-templating and cycling elements: geometric (2^n) rather than linear accumulation, and ~10^6-fold amplification in ~20 cycles, is a qualitative departure from D1/D2 single-pass extension — this ties to the specific claimed 'each product serves as template for the other primer' feature.
  • Teaching-away / skepticism — nexus: Any assertion that the field expected only linear or clone-based amplification rests on an uncorroborated asserted norm; a reference showing others already cycled flanking primers would defeat it — no provided reference establishes such skepticism, so this carries no independent weight as presented.
    • ⚠ See the Inventive-Step Stress Test premise audit — retrieved art contradicts this teaching-away premise as stated; counsel should reframe it per that section rather than relying on it here.
  • Commercial success — nexus: No nexus established on this record; not supported by any provided evidence.

Standard: §103 obviousness (for counsel to assess). Note: several retrieved references (e.g., US20220033891A1, US11466315B2, CN114250278B, CN116121349B, and the 1990/1992/2003/2005/2018/2024 papers) appear to postdate this origin-field invention and likely do not qualify as §103 prior art — counsel should verify each reference's effective date; the operative prior art here is the cited background D1–D4.

Molecular measurement / quantitation — Determining how much of a target sequence is present in a sample — e.g., pathogen load, gene copy number, or transcript abundance — by relating the cycle count needed to reach a set amount back to the starting quantity.

Closest existing work: Retrieved qPCR references that quantify a target by relating amplification cycles to starting amount — CN114250278B (pre-amplification of 2–14 cycles followed by quantitative real-time PCR) and US11466315B2 (two primers annealing to complementary strands plus an indicator molecule reporting the amount of nucleic acid). All of the retrieved quantitation art sits downstream of and relies upon the two-primer exponential engine defined by the invention.

Differentiation: At the claim level, those references presuppose and build on the invention's named core elements — two flanking primers complementary to opposite strands, primer-extension product of one serving as template for the other, molar-excess primers, and the repeated denature/anneal/extend cycle giving geometric (~2^n) accumulation over a primer-bounded region; the retrieved art adds detection/readout layers (real-time indicator, pre-amplification-then-qPCR) rather than disclosing that underlying exponential amplification mechanism itself. The quantitation use here is simply exploiting the invention's own defined exponential relationship (cycles-to-threshold ∝ starting template) — abstract-level as to what the cited art independently teaches. §102/§103 for counsel to assess.

Triage: spec support only — a predictable same-mechanism use; valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim

Citations:

  • CN114250278B (verify) — Quantifies target by qPCR after a defined-cycle pre-amplification using forward/reverse primer pairs — quantitation built directly on the two-primer exponential mechanism (provenance: grounded)
  • US11466315B2 (verify) — Two primers annealing to complementary strands of dsDNA through denature/anneal/extend cycles, with an indicator molecule reporting nucleic-acid amount — the same core engine used for measurement (provenance: grounded)
  • US20220033891A1 (verify) — Forward/reverse primer amplification with target serving as template producing a primer-bounded predominant product — mirrors the bounded-region two-primer architecture (provenance: grounded)

Standard: §102 novelty (for counsel to assess)

Condensed entry: triaged spec-support-only, so the full §103 positioning is reserved for claim-candidate applications and the origin field.

Inherited-disease and prenatal genetic testing — Amplifying a specific gene region from a limited clinical sample (few cells, biopsy, or fetal-derived material) so a mutation or variant can be analyzed without culturing cells.

Closest existing work: For this diagnostic application, the closest prior approach is cloning-based amplification by propagation in a host organism (D3) — the prior route to obtaining analyzable quantities of a gene region from a limited sample — plus prior single-primer linear extension (D1) and repair-replication (D2), all disclosed as background.

Differentiation: Against D3, the invention obtains analyzable quantities of the diagnostic locus entirely in-vitro without host propagation or cloning, using the two flanking primers in molar excess and repeated denature/hybridize/extend thermal cycling so each product becomes a template (exponential ~2^n accumulation); against D1/D2 the named two-primer bounded-region architecture and reciprocal template roles distinguish the single-primer/linear background art. This is abstract-level differentiation for the cited background references (D1–D4 have no claim text provided).

Triage: spec support only — a predictable same-mechanism use; valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim

Citations:

  • D3 — The prior means of getting analyzable amounts of a locus from limited clinical material was host-cell propagation/cloning; the invention replaces this with in-vitro exponential amplification — the core contrast for the diagnostic use case. (provenance: grounded)
  • D1 — Single-primer linear extension background; the invention's two-primer reciprocal-template, bounded-region exponential mechanism is the distinguishing feature. (provenance: grounded)
  • D2 — Repair-replication background disclosed by inventor; lacks the two-flanking-primer exponential cycling architecture. (provenance: grounded)

Standard: §102 novelty (for counsel to assess)

Inventive-step consideration (§103 argument): Under §103, the question is whether the diagnostic use — amplifying a specific gene region from a few clinical cells so a mutation can be read without culturing — would have been a predictable application of the two-primer exponential cycling mechanism over D1–D4. The named novel elements (bounded-region architecture defined by two flanking primers, geometric 2^n accumulation, large primer:template molar excess up to ~1e6:1 for genomic DNA, and entirely in-vitro amplification without host propagation) are properties of the core method itself; the genetic-testing application chiefly supplies a target and a motivation, so the argument should locate any non-obviousness in the mechanism rather than in the clinical use per se.

Articulated reason (KSR): A PHOSITA would have had clear reason to apply an in-vitro exponential amplification method to inherited-disease/prenatal testing because D3 (cloning-based propagation) is expressly characterized as laborious, low-efficiency, and hazardous with delay — an articulated motivation to obtain analyzable quantities from scarce fetal or biopsy material without culturing; however, D1 (single-primer linear extension) and D2 (repair-replication) provide only linear or non-exponential outputs and do not supply the two-primer reciprocal-templating, molar-excess, cyclic architecture that produces geometric accumulation, so the combination furnishing the bounded-region exponential mechanism is not laid out by the cited background itself.

Reasonable expectation of success: Given the disclosed data-backed demonstrations (~15 cycles at ~70% per-cycle efficiency, ~1e6-fold amplification after ~20 cycles from cloned DNA), a PHOSITA would have a reasonable expectation that the same cycling scheme yields analyzable quantities from a defined locus; expectation for the genomic/clinical sample case is weaker and more forward-looking, since amplification from genomic DNA at up to ~1e6:1 excess is described-not-demonstrated and specificity/yield from a single-copy locus in a complex genome is not shown in the provided record.

Secondary considerations (each needs a nexus):

  • Long-felt need — nexus: Strong nexus — the ability to obtain analyzable amounts of a specific locus from few cells without cell propagation directly ties to the in-vitro, bounded-region, exponential-from-scarce-template features; D3's characterization as laborious/hazardous corroborates the need rather than resting on a bare assertion.
  • Unexpected results — nexus: Potential nexus to the ~2^n geometric accumulation and ~1e6-fold yield producing diagnostic quantities from minimal starting material, a result the linear D1/D2 methods could not deliver; nexus to the clinical application specifically is not independently established beyond the underlying mechanism.
  • Commercial success — nexus: No nexus established on the provided record — no evidence tying commercial adoption in genetic testing to the claimed features is present here.
  • Teaching away — nexus: None identified in the provided references; any assertion that the field expected cell culture to be necessary rests on an uncorroborated asserted norm — a reference showing in-vitro amplification was already contemplated would defeat it.
    • ⚠ See the Inventive-Step Stress Test premise audit — retrieved art contradicts this teaching-away premise as stated; counsel should reframe it per that section rather than relying on it here.

Standard: §103 obviousness (for counsel to assess)

Research / biotechnology enabling workflows — Rapidly generating usable quantities of a defined sequence for cloning inserts, sequencing template preparation, synthetic gene assembly, and primer-directed sequence editing.

Closest existing work: The incumbent for generating usable quantities of a defined sequence in research workflows is host-organism cloning/propagation (D3) and prior single-primer linear primer-extension (D1); D3 makes material by biological propagation, and D1 uses only one primer so the product does not itself become a template.

Differentiation: Abstract-level (cited background only): unlike D3's in-host propagation and D1's single-primer linear extension, this invention's named elements — two flanking primers each complementary to a different strand in molar excess, each extension product serving as template for the other primer, and the repeated denature(~80–105°C)/anneal/extend cycle — produce host-free geometric (~2^n) accumulation of a segment bounded by the two primer sites; none of D1–D4 disclose the two-primer product-as-template exponential cycle (§102 novelty / §103 for counsel to assess).

Triage: spec support only — a predictable same-mechanism use; valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim

Citations:

  • D3 — Cited background — cloning-based amplification by host propagation; the incumbent this in-vitro cycle replaces for producing sequence material, but lacks any two-primer thermal cycling. (provenance: grounded)
  • D1 — Cited background — single-primer linear extension; closest primer-extension art but lacks the second flanking primer and product-becomes-template exponential feature. (provenance: grounded)
  • D2 — Cited background — repair-replication; related enzymatic copying but no two-primer bounded exponential cycling. (provenance: grounded)
  • US11466315B2 (verify) — Two-primer denature/anneal/extend cycling amplification (STR) — same core mechanism but appears to post-date; verify temporal status before relying on it. (provenance: verify_full_doc)

Standard: §102 novelty (for counsel to assess)

Inventive-step consideration (§103 argument): For this manufacturing/editing application, the §103 inquiry weighs whether combining the disclosed background — single-primer linear extension (D1), repair-replication (D2), and the recognized inadequacy of host-propagation (D3) and de-novo synthesis (D4) for producing usable quantities — renders obvious the two-primer, reciprocal-template, cyclic exponential architecture used to prepare cloning inserts and sequencing templates; the retrieved amplification patents/papers (e.g. US20220033891A1, EXPAR 2018, LATE-PCR 2005) largely postdate and build upon the core function, so they inform the field's later state rather than supplying a pre-invention teaching to combine.

Articulated reason (KSR): A PHOSITA aware of D1's single-primer extension and dissatisfied with D3/D4's laborious, low-efficiency material production had a motivation to enzymatically generate defined segments in vitro; however, D1–D2 describe linear or repair processes and none articulates the specific step of using each primer's extension product as template for the other primer under repeated denature/anneal/extend cycling — the geometric (∼2^n) accumulation and bounded-region delimitation are not a mere predictable substitution but the added structural insight for which no cited reference supplies a reason.

Reasonable expectation of success: A PHOSITA would have expected primer hybridization and polymerase extension individually to work (established in D1/D2), but would not necessarily have predicted robust exponential accumulation of a discretely bounded product across repeated thermal denaturation (85–100 °C) cycles — the demonstrated ∼70%/cycle efficiency and ∼1e6-fold yield after ∼20 cycles supply the specifics; expectation for the described-only genomic-DNA (∼1e6:1) and broad 80–105 °C embodiments is weaker as those are not data-backed.

Secondary considerations (each needs a nexus):

  • Long-felt need / failure of prior approaches — nexus: D3 (host-organism cloning) and D4 (de-novo synthesis) are characterized in the disclosure as laborious and low-efficiency; the in-vitro exponential cycle directly addresses that need for the cloning/sequencing-prep use — nexus is to the claimed cyclic exponential architecture, though the 'laborious/low-efficiency' characterization rests partly on the inventor's own disclosure and should be corroborated by an independent reference.
  • Unexpected results — nexus: Geometric (∼2^n − n − 1) accumulation versus the linear output of D1's single-primer extension ties directly to the reciprocal-template two-primer feature — the quantitative leap in yield is the claimed advance, not attributable to any single cited reference.
  • New capability enabling the application (sequence editing / defined inserts) — nexus: The bounded-region architecture and primer-carried engineered changes enable defined-insert and editing workflows that D3/D4 do not efficiently provide — nexus is strong to the two-primer-defined-boundary feature, but this capability is described_not_demonstrated here, so weight depends on enablement.
  • Commercial success — nexus: No nexus established on this record — no evidence of commercial adoption tied to the claimed features is provided in the references.

Standard: §103 obviousness (for counsel to assess)

Forensic and identity DNA analysis — Amplifying identity-informative loci from trace, mixed, or partially degraded biological material recovered from crime scenes, disaster remains, or kinship/paternity samples.

Closest existing work: US11466315B2 ('Fast PCR for STR genotyping') is the closest — it applies two-primer thermal-cycling amplification (denature/anneal/extend) directly to forensic STR and amelogenin loci, i.e. the exact identity-typing use here. The retrieved 'Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase' paper describes the same core two-primer exponential cycling mechanism generally.

Differentiation: Abstract/claim-level: US11466315B2 presupposes the invention's named core elements (two primers annealing to complementary strands, primer extension, denaturation cycling, bounded product) and adds forensic-specific refinements it claims as limitations — antibody-bound Taq at 0.3–0.4 U/µl and a ≤25-second cycle time — none of which are the invention's named elements; the invention here is the underlying two-primer, molar-excess, treat/extend/separate exponential mechanism with ~85–100 °C denaturation and near-ambient hybridization producing the bounded region, not the fast-cycling STR optimization. For counsel to assess under §102/§103.

Triage: spec support only — a predictable same-mechanism use; valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim

Citations:

  • US11466315B2 (verify) — Directly forensic STR genotyping using two primers annealing to complementary strands with denature/anneal/extend cycling — same core mechanism applied to the identity-typing loci at issue; distinguished by its added fast-cycle/enzyme-concentration limitations (provenance: grounded)
  • US20220033891A1 (verify) — Two-primer (forward/reverse) amplification of a bounded target segment via primer extension with target as template — same bounded-region two-primer architecture (provenance: grounded)

Standard: §102 novelty (for counsel to assess)

Condensed entry: triaged spec-support-only, so the full §103 positioning is reserved for claim-candidate applications and the origin field.

Oncology / liquid biopsy — Detecting rare tumor-derived molecules (e.g., mutant sequences) among a large background of normal cell-free fragments circulating in blood or other body fluids.

Closest existing work: General primer-directed thermal-cycling amplification using two flanking primers on complementary strands — the core mechanism itself, reflected in the retrieved two-primer/thermostable-polymerase amplification art (e.g., the 'Primer-Directed Enzymatic Amplification' paper) and applied downstream in STR/qPCR detection patents; none of the retrieved references is directed to trace tumor-molecule detection in body fluids.

Differentiation: This is the same named two-primer, molar-excess, treat/extend/separate exponential mechanism (2^n−n−1 accumulation, bounded product delimited by two primer sites) simply deployed to amplify rare mutation-bearing cell-free fragments above a normal background; abstract-level comparison — the retrieved art shows the identical core cycling but the liquid-biopsy deployment adds no new named element to the mechanism itself. §102 novelty and §103 obviousness for counsel to assess.

Triage: spec support only — a predictable same-mechanism use; valuable as disclosure / spec breadth, but unlikely to support its own non-obvious claim

Citations:

  • Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase (paper) — Discloses the same two-primer, thermal-cycling, template-copying exponential amplification that is the core mechanism being deployed here. (provenance: grounded)
  • US11466315B2 (verify) — Two-primer denature/anneal/extend cycling on complementary strands of a double-stranded target — same core cycle, shows the mechanism is generic to detection applications. (provenance: grounded)
  • US20220033891A1 (verify) — Forward/reverse primer amplification producing a bounded predominant segment defined by primer binding sites — parallels the bounded-region architecture element. (provenance: grounded)

Standard: §102 novelty (for counsel to assess)

Condensed entry: triaged spec-support-only, so the full §103 positioning is reserved for claim-candidate applications and the origin field.

6.

Candidate Filings & Family Structure

Filing Strategy

File one comprehensive 'jumbo' provisional that bundles the core two-primer geometric amplification engine and every disclosed downstream deployment (clinical diagnostics, quantitation, genetic testing, research workflows, forensics, liquid biopsy). Anchor it on the data_backed exponential-amplification embodiments so the shared detailed description carries maximum weight from day one. Within the 12-month non-extendable window, convert the shared description into a US non-provisional and a PCT, each drawing on the SAME detailed description but with DIFFERENTIATED CLAIM SETS (broad method/apparatus claims plus field-tailored use claims). The single shared specification is what lets each conversion reduce the per-conversion attorney drafting fee rather than paying a full independent spec cost per filing. Foreign coverage rides the PCT (12-month priority, 30-month national phase). Continuations/divisionals later carve out field-specific or restriction-driven claim sets from the same disclosure.

Recommended Filings

  • provisional — Jumbo provisional covering the core two-primer exponential amplification method (data_backed: ~1000:1 primer:template, heat denaturation, ambient hybridization, low-temp extension, 13-20 cycles, ~1e6-fold after ~20 cycles, ~70% per-cycle efficiency) plus the full menu of downstream applications (Apps 1-6) as described.

    • Establishes the earliest possible priority date across the whole moat in a single non-examined filing. Origin-field clinical diagnostics (App 1) is the file-first use where the closest/most dangerous prior art lives, so front-loading the core engine there is the primary defensive move. Bundling the adjacent uses now preserves optionality before the 12-month clock (verify with counsel).

  • non_provisional — US filing off the shared detailed description. Broad independent claims to the amplification method (data-backed embodiments), with dependent/field-specific claim sets for clinical diagnostics, genetic testing, and research workflows.

    • Converts the provisional within the non-extendable 12-month window. Claim differentiation concentrates protection on the well-supported near-field uses first; adjacent speculative uses claimed only to the extent the disclosure supports them.

  • pct — International filing off the SAME shared description, preserving the option to enter national phase in relevant jurisdictions with locally tailored claim sets.

    • Reuses the shared spec for foreign coverage (12-month priority, 30-month national phase — verify with counsel), deferring per-country cost while keeping the moat global.

  • divisional — Reserved for restriction-driven separation if the examiner deems method vs. quantitation vs. use claims independent/distinct.

    • Inherits the priority date; used only if a restriction requirement forces the field-specific claim sets apart.

  • continuation — Later capture of additional claim scope (e.g., liquid-biopsy or forensic use claims) fully supported by the original shared disclosure, with no new matter.

    • Inherits the original date; keeps prosecution alive to pursue adjacent-field claims as commercial priorities firm up, without a new filing date.

Disclosure Gaps (per application)

  • Clinical infectious-disease diagnostics (App 1) (described_not_demonstrated): Worked examples amplifying an actual pathogen-specific bounded region from a patient-representative specimen; sensitivity/limit-of-detection data at trace pathogen levels and specificity data against non-target templates. Current disclosure is genomic-DNA amplification described but not demonstrated for pathogen targets.

  • Molecular measurement / quantitation (App 2) (speculative): Data linking cycle-count-to-threshold back to known starting quantities across a dilution series (a standard/calibration curve), plus reproducibility of the ~70% per-cycle efficiency assumption underpinning the exponential relationship. Presently only the doubling relationship is described, not a demonstrated quantitative read-out.

  • Inherited-disease and prenatal genetic testing (App 3) (described_not_demonstrated): Demonstration of amplifying a specific human gene locus from limited/scarce clinical material (few cells, biopsy, fetal-derived), plus evidence the bounded product isolates the diagnostically relevant region well enough for mutation/variant analysis.

  • Research / biotechnology enabling workflows (App 4) (described_not_demonstrated): Examples showing produced material used for cloning inserts, sequencing template prep, or primer-directed sequence editing — in particular data confirming initiator-carried engineered changes are incorporated into the product.

  • Forensic and identity DNA analysis (App 5) (speculative): Performance data on degraded/fragmented and mixed templates, amplification of identity-informative loci, and behavior at vanishingly small input amounts typical of trace crime-scene material. Different professional field warrants field-tailored use claims once supported.

  • Oncology / liquid biopsy (App 6) (speculative): Data showing selective amplification of rare mutant/tumor-derived sequences above a large background of normal cell-free fragments — i.e., allele/mutation discrimination and rare-target sensitivity from body-fluid-representative samples.

7.

Grounding & Search Log

Grounding Summary

Note

Of 6 application(s) analyzed for prior art:

  • 6 grounded (claim text was available for 5 of 14 retrieved references; the comparison is abstract-level for the rest)

This site uses cookies to improve your experience.